Skip to content

Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father

Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06772701
Acronym
EPDS-PERE
Enrollment
1000
Registered
2025-01-13
Start date
2024-07-11
Completion date
2027-03-12
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Postpartum

Brief summary

In recent years, fatherhood has changed considerably. Fathers are now more involved during the perinatal period, with their partner but also in caring for the child. Investigators now know that this period is also a source of major psychological upheaval, identity crisis, apprehension and anxiety for men. These upheavals can lead to depression that must be detected and treated as early as possible. This is an easy screening to perform using the EPDS (Edinburgh Postnatal Depression Scale). Currently, the EPDS is the most widely used self-questionnaire to assess the risk of depression in women during the perinatal period. Indeed, it is systematically recommended in many countries. It is starting to be used for the same purpose in the perinatal period in men, although the scale has not been validated in a representative sample of men in the pre- or post-natal period. The main objective is to validate the use of the EPDS scale as a screening tool for postnatal depression in a population of French fathers. They complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

Detailed description

Fathers complete the PH-Q9, EPDS and socio-demographic questionnaires online at inclusion and 6 to 8 weeks after the birth of their child. Fathers included at the maternity ward also too Mini International Neuropsychiatric Interview (MINI) at inclusion.

Interventions

Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression

OTHEREPDS book

PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.

Sponsors

Groupe Hospitalier du Havre
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

Fathers included at the maternity hospital or through the mother take the Mini International Neuropsychiatric Interview and complete the PH-Q9, EPDS and socio-demographic questionnaires. Fathers included through the awareness campaign have only the PH-Q9, EPDS and socio-demographic questionnaires.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All fathers whose baby is 10 days old or less

Exclusion criteria

* People with a poor understanding of spoken or written French * Minors * Persons under court protection, guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Mini International Neuropsychiatric Interviewat inclusionThis short structured clinical interview is used to diagnose psychiatric disorders and is currently the gold standard for diagnosing depression.

Secondary

MeasureTime frameDescription
socio-demographic questionnaireat inclusion and 6 to 8 weeks after the birth of their childSocio-demographic data will be a secondary evaluation criterion. It will be used to study risk and protective factors, both those already known in the literature and those that have been little studied, and to identify profiles that are more at risk, with a view to taking preventive action in the field.

Countries

France

Contacts

CONTACTAngélique PICARD, project coordinator
angelique.picard@ch-havre.fr+33232734856
CONTACTChristophe FRUIT, CRA
cellule.rechercheclinique@ch-havre.fr+33232734857

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026